Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019043108) CANCER TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/043108 International Application No.: PCT/EP2018/073365
Publication Date: 07.03.2019 International Filing Date: 30.08.2018
IPC:
A61K 31/4184 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
REPOS PHARMA AB [SE/SE]; Dag Hammarskjölds Väg 40 C 75237 Uppsala, SE
Inventors:
FRYKNÄS, Mårten; SE
LARSSON, Rolf; SE
NYGREN, Peter; SE
Agent:
ABEL & IMRAY; Westpoint Building James Street West Bath Bath and North East Somerset BA1 2DA, GB
Priority Data:
1713852.030.08.2017GB
Title (EN) CANCER TREATMENT
(FR) TRAITEMENT CONTRE LE CANCER
Abstract:
(EN) The present invention provides a use of a mebendazole for treating cancer, wherein the treatment comprises administering a dose of mebendazole to the patient sufficient to achieve a steady state maximum plasma concentration (Cmax) of mebendazole of 150 - 350 ng/ml (for example 150 - 250, 200 - 300 or 250 - 350 ng/ml). The invention further provides methods for treating cancer, and methods for establishing a therapeutic dose in a patient having cancer.
(FR) La présente invention concerne l'utilisation de mébendazole pour traiter le cancer, le traitement comprenant l'administration au patient d'une dose de mébendazole suffisante afin d'obtenir une concentration plasmatique maximale à l'état d'équilibre (Cmax) du mébendazole de 150 à 350 ng/ml (par exemple de 150 à 250, de 200 à 300 ou de 250 à 350 ng/ml). L'invention concerne en outre des méthodes de traitement du cancer, et des procédés d'établissement d'une dose thérapeutique chez un patient atteint d'un cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)